Back to top
more

Envista (NVST)

(Delayed Data from NYSE)

$19.28 USD

19.28
1,735,443

+0.45 (2.39%)

Updated May 9, 2024 04:00 PM ET

After-Market: $19.29 +0.01 (0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 43% (142 out of 250)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Envista (NVST) Q1 Earnings Miss Estimates, Margins Down

by Zacks Equity Research

Envista (NVST) registers a year-over-year decline in both segments in the first quarter of 2024.

Here's What Key Metrics Tell Us About Envista (NVST) Q1 Earnings

by Zacks Equity Research

The headline numbers for Envista (NVST) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Envista (NVST) Lags Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Envista (NVST) delivered earnings and revenue surprises of -16.13% and 0.87%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Envista (NVST) Faces Macroeconomic Challenges, FX Headwind

by Zacks Equity Research

The challenging macroeconomic conditions are resulting in a significant escalation in Envista's (NVST) costs and expenses.

Envista (NVST) Down 5.8% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Envista (NVST) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Envista (NVST) Q4 Earnings Miss Estimates, Margins Down

by Zacks Equity Research

Strong performance in the Speciality Products & Technologies segment contributes to Envista's (NVST) Q4 revenues.

Envista (NVST) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates

by Zacks Equity Research

Although the revenue and EPS for Envista (NVST) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Urmimala Biswas headshot

Medical Products Stocks' Earnings Due on Feb 7: STE, PAHC & NVST

by Urmimala Biswas

Medical Products companies' quarterly results are likely to reflect a year-over-year decline in earnings. Let's see how STE, PAHC and NVST fare this time.

Curious about Envista (NVST) Q4 Performance? Explore Wall Street Estimates for Key Metrics

by Zacks Equity Research

Besides Wall Street's top -and-bottom-line estimates for Envista (NVST), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2023.

Haemonetics (HAE) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Haemonetics (HAE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Envista (NVST) Q4 Earnings Expected to Decline

by Zacks Equity Research

Envista (NVST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

New Strong Sell Stocks for December 21st

by Zacks Equity Research

DSKE, NVST and HENKY have been added to the Zacks Rank #5 (Strong Sell) List on December 21, 2023.

Envista (NVST) Up 6.8% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Envista (NVST) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Envista (NVST) Q3 Earnings Miss Estimates, Gross Margin Down

by Zacks Equity Research

Envista's (NVST) Q3 performance is impacted by the negative impact of Russia and the weakness of higher-end specialty procedures in developed markets.

Compared to Estimates, Envista (NVST) Q3 Earnings: A Look at Key Metrics

by Zacks Equity Research

While the top- and bottom-line numbers for Envista (NVST) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Urmimala Biswas headshot

MedTech Stocks' Q3 Earnings Due on Nov 1: IDXX, EXAS & More

by Urmimala Biswas

MedTech companies' third-quarter results are likely to reflect a year-over-year decline. Let's see how IDXX, EXAS, TNDM and NVST fare this time.

Select Medical (SEM) Q2 Earnings Meet, Revenues Rise Y/Y

by Zacks Equity Research

Select Medical's (SEM) Q2 results reflect solid segmental revenues, attributable to higher patient days and outpatient visits. Management projects adjusted EPS of $1.86-$2.03 for 2023.

Envista (NVST) Q2 Earnings Top Estimates, Margins Expands

by Zacks Equity Research

Consistent growth in the Specialty Products & Technologies segment and a return to growth in the Equipment & Consumables segment drive Envista's (NVST) Q2 revenues.

Envista (NVST) Reports Q2 Earnings: What Key Metrics Have to Say

by Zacks Equity Research

Although the revenue and EPS for Envista (NVST) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Envista (NVST) Beats Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Envista (NVST) delivered earnings and revenue surprises of 4.88% and 1.81%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Envista (NVST) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

by Zacks Equity Research

Envista (NVST) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Envista (NVST) Gains From New Acquisitions Amid FX Woes

by Zacks Equity Research

Envista's (NVST) implant businesses in Europe perform well on the back of disciplined commercial execution.

Envista (NVST) Q1 Earnings Miss Estimates, Margins Down

by Zacks Equity Research

Weakness in China and Russia and lower demand for large capital equipment hurts Envista's (NVST) Q1 revenues.

Envista (NVST) Q1 Earnings and Revenues Miss Estimates

by Zacks Equity Research

Envista (NVST) delivered earnings and revenue surprises of -7.32% and 0.59%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Envista (NVST) Surpasses Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Envista (NVST) delivered earnings and revenue surprises of 6.12% and 0.02%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?